Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.34 |
| ▸ | IDH2 | P48735 | 5/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646151 | 0.77 | GABRA1 (0.36) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL31078226 | 0.77 | IDH1 (0.37) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL30041313 | 0.77 | GABRA1 (0.36) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL1437359 | 0.77 | IDH1 (0.37) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL906764 | 0.77 | GABRA1 (0.36) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL31691830 | 0.77 | HTR7 (0.30) | — | |
| SCHEMBL860147 | 0.75 | IDH1 (0.32) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21296390 | 0.74 | GABRA1 (0.34) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL29427057 | 0.73 | HTR7 (0.35) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL37428 | 0.73 | GABRA1 (0.47) | IDH1IDH2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4522612-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | IDH1 1663/4885IDH2 1903/4885GABRA1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.